Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Authors: Lee, Chung-Han ^*, Shah, Amishi Yogesh, Rasco, Drew, Rao, Arpit, Taylor, Matthew H, Di Simone, Christopher, Hsieh, James J, Pinto, Alvaro, Shaffer, David R, Girones Sarrio, Regina, Cohn, Allen Lee, Vogelzang, Nicholas J, Bilen, Mehmet Asim, Gunnestad Ribe, Sara, Goksel, Musaberk, Tennøe, Øyvind Krohn, Richards, Donald, Sweis, Randy F, Courtright, Jay, Heinrich, Daniel, Jain, Sharad, Wu, Jane, Schmidt, Emmett V, Perini, Rodolfo F, Kubiak, Peter, Okpara, Chinyere E, Smith, Alan D, Motzer, Robert J

Source: In The Lancet Oncology July 2021 22(7):946-958

Immune checkpoint inhibitors (ICIs) in advanced upper tract urothelial cancer (UTUC) with mismatch repair deficiency (dMMR) or microsatellite instability (MSI).

Authors: Moussa, Mohammad Jad, Andreev-Drakhlin, Alexander, Shah, Amishi Yogesh, Matin, Surena F., Adriazola, Ana Cecilia, Shaw, Leah, Campbell, Marihella L., Msaouel, Pavlos, Corn, Paul Gettys, Lin, John Kent, Goswami, Sangeeta, Gao, Jianjun, Guo, Charles C., Tannir, Nizar M., Siefker-Radtke, Arlene O., Alhalabi, Omar, Campbell, Matthew T.

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p818-818, 242p

Metastasis-directed radiotherapy in oligometastatic bladder and upper tract cancer: A single institution retrospective experience.

Authors: Carriere, Patrick, Alhalabi, Omar, Gao, Jianjun, Shah, Amishi Yogesh, Campbell, Matthew T., Mayo, Lauren L., Mohamad, Osama, Hoffman, Karen E., Mok, Henry, Lozano, Charmaigne, Shah, Shalin J., Park, Ryan Jin-hyung, Mcguire, Sean Eric, Kamat, Ashish M., Navai, Neema, Bree, Kelly K., Guo, Charles C., Tang, Chad, Choi, Seungtaek, Hassanzadeh, Comron

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p799-799, 242p

Efficacy and safety of nivolumab plus ipilimumab (Nivo/Ipi) in patients with metastatic variant histology renal cell carcinoma.

Authors: Moussa, Mohammad Jad, Khandelwal, Jaanki, Wilson, Nate, Malikayil, Kiran Luke, Surasi, Devaki Shilpa, Bathala, Tharakeswara K., Lin, Yiyun, Ajufo, Helen, Elsayes, Khaled M., Shah, Amishi Yogesh, Johns, Andrew, Goswami, Sangeeta, Hasanov, Elshad, Jonasch, Eric, Msaouel, Pavlos, Campbell, Matthew T., Alhalabi, Omar, Tannir, Nizar M.

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p558-558, 177p

Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.

Authors: Motzer, Robert J., Escudier, Bernard, Burotto, Mauricio, Powles, Thomas, Apolo, Andrea B, Bourlon, Maria T., Shah, Amishi Yogesh, Porta, Camillo, Suárez, Cristina, Barrios, Carlos H., Richardet, Martin Eduardo, Gurney, Howard, Kessler, Elizabeth R., Tomita, Yoshihiko, Bedke, Jens, Rangwala, Fatima A., Askelson, Margarita, Panzica, Julie, Fedorov, Viktor, Choueiri, Toni K.

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p439-439, 177p

A phase II study bolstering outcomes by optimizing immunotherapy strategies with evolocumab and nivolumab in patients with metastatic renal cell carcinoma (BOOST-RCC).

Authors: Zhang, Tian, Qin, Qian, Cole, Suzanne, Wang, Andrew Zhuang, Msaouel, Pavlos, Hahn, Andrew Warren, Shah, Amishi Yogesh, Campbell, Matthew T., Zhang, Song, Tidwell, Rebecca Slack, Issa, Wadih, DeVilbiss, Andrew, Jiang, Changchuan, Vento, Joseph, Courtney, Kevin Dale, Hammers, Hans J., Brugarolas, James, Tannir, Nizar M., Jonasch, Eric

Source: Journal of Clinical Oncology; 2/10/2025 Supplement5, Vol. 43, pTPS612-TPS612, 177p

The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) + ipilimumab (ipi).

Authors: Grewal, Kabir, Chauhan, Pankaj Kumar, Mukhida, Sagar S, Tannir, Nizar M., Venkatesh, Neha, Shah, Amishi Yogesh, Zurita, Amado J., Johns, Andrew, Campbell, Matthew T., Goswami, Sangeeta, Gao, Jianjun, Jonasch, Eric, McQuade, Jennifer Leigh, Alhalabi, Omar, Msaouel, Pavlos, Hahn, Andrew Warren

Source: Journal of Clinical Oncology; 2/10/2025 Supplement5, Vol. 43, p545-545, 177p

Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract: The MD Anderson Cancer Center (MDACC) experience.

Authors: Moussa, Mohammad Jad, Chen, Adrienne H., Grana, Allison K., Gao, Jianjun, Shah, Amishi Yogesh, Corn, Paul Gettys, Tannir, Nizar M., Goswami, Sangeeta, Wang, Jianbo, Araujo, John C., Kamat, Ashish M., Navai, Neema, Pettaway, Curtis Alvin, Adibi, Mehrad, Czerniak, Bogdan, Guo, Charles C., Siefker-Radtke, Arlene O., Campbell, Matthew T, Alhalabi, Omar

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p630-630, 193p

Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).

Authors: Johns, Andrew, Campbell, Matthew T, Gao, Mamie, Lim, Zita Dubauskas, Wang, Emily, Hahn, Andrew Warren, Gao, Jianjun, Shah, Amishi Yogesh, Msaouel, Pavlos, Tannir, Nizar M.

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p419-419, 140p

Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN+PEM).

Authors: Haro-Silerio, Jaime Ivan, Johns, Andrew, Moussa, Mohammad Jad, Wang, Mindy, Wang, Emily, Kovitz, Craig A., Campbell, Matthew T, Jonasch, Eric, Shah, Amishi Yogesh, Tannir, Nizar M.

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p433-433, 140p

Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.

Authors: Bourlon, Maria Teresa, Escudier, Bernard, Burotto, Mauricio, Powles, Thomas, Apolo, Andrea B., Shah, Amishi Yogesh, Porta, Camillo, Suárez, Cristina, Barrios, Carlos H., Richardet, Martin, Gurney, Howard, Kessler, Elizabeth R., Tomita, Yoshihiko, Bedke, Jens, Wang, Fong, Wang, Peter, Panzica, Julie, Fedorov, Viktor, Motzer, Robert J., Choueiri, Toni K.

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p362-362, 140p

Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis.

Authors: Saji, Alice, Chopra, Maneera, Jacob, Jake, Altan, Mehmet, Alhalabi, Omar, Shah, Amishi Yogesh, Qiao, Wei, Wang, Yinghong, Thomas, Anusha

Source: Journal of Cancer Research & Clinical Oncology; Aug2023, Vol. 149 Issue 9, p5841-5852, 12p

Subject Terms: COLITIS, IMMUNE checkpoint inhibitors, TREATMENT effectiveness, DIARRHEA, IMMUNOTHERAPY, CLINICAL trials monitoring, DISEASE remission

A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.

Authors: Msaouel, Pavlos, Goswami, Sangeeta, Thall, Peter F., Wang, Xuemei, Yuan, Ying, Jonasch, Eric, Gao, Jianjun, Campbell, Matthew T., Shah, Amishi Yogesh, Corn, Paul Gettys, Tam, Alda L., Ahrar, Kamran, Rao, Priya, Sircar, Kanishka, Cohen, Lorenzo, Basu, Sreyashi, Duan, Fei, Jindal, Sonali, Zhang, Yuwei, Chen, Hong

Source: Science Translational Medicine; 4/20/2022, Vol. 14 Issue 641, p1-11, 11p

Subject Terms: RENAL cell carcinoma, NIVOLUMAB, MYELOID cells, IMMUNE checkpoint proteins, PROTEIN-tyrosine kinase inhibitors, PROGRAMMED cell death 1 receptors

Final database lock results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma.

Authors: Lee, Chung-Han, Shah, Amishi Yogesh, Rao, Arpit, Taylor, Matthew H, Pinto, Alvaro, Sarrio, Regina Girones, Cohn, Allen Lee, Bilen, Mehmet Asim, Ribe, Sara Gunnestad, Goksel, Musaberk, Tennøe, Øyvind Krohn, Richards, Donald, Sweis, Randy F, Heinrich, Daniel, Perini, Rodolfo, Kubiak, Peter, Huang, Jie, Motzer, Robert J

Source: Oncologist; 2023 Supplement 1, Vol. 28, pS3-S4, 2p, 1 Chart, 1 Graph

Subject Terms: THERAPEUTIC use of monoclonal antibodies, RENAL cell carcinoma, PROGRAMMED cell death 1 receptors, PROGRAMMED death-ligand 1, METASTASIS, CONFERENCES & conventions, PROTEIN-tyrosine kinase inhibitors, TREATMENT effectiveness

Geographic Terms: MASSACHUSETTS

Nivolumab for the Treatment of Patients with Metastatic Non‐Clear Cell Renal Cell Carcinoma (nccRCC): A Single‐Institutional Experience and Literature Meta‐Analysis.

Authors: Chahoud, Jad, Msaouel, Pavlos, Campbell, Matthew T., Bathala, Tharakeswara, Xiao, Lianchun, Gao, Jianjun, Zurita, Amado J., Shah, Amishi Yogesh, Jonasch, Eric, Sharma, Padmanee, Tannir, Nizar M.

Source: Oncologist; Mar2020, Vol. 25 Issue 3, p252-258, 7p, 3 Charts, 2 Graphs

Subject Terms: ANTINEOPLASTIC agents, CANCER patients, CONFIDENCE intervals, DIAGNOSTIC imaging, IMMUNOTHERAPY, MEMBRANE proteins, META-analysis, RENAL cell carcinoma, SURVIVAL, TREATMENT effectiveness, DISEASE remission, DESCRIPTIVE statistics

Management of Advanced Bladder Cancer: An Update.

Authors: LEMKE, EMILY A., SHAH, AMISHI YOGESH

Source: JADPRO: Journal of the Advanced Practitioner in Oncology; May/Jun2018, Vol. 9 Issue 4, p410-416, 7p

Doxorubicin, paclitaxel, and cisplatin (ATP) for refractory germ cell tumors.

Authors: Xiang, Jenny Jing, Campbell, Matthew T, Tu, Shi-Ming, Araujo, John C., Nieto, Yago, Lin, John Kent, Xiao, Lianchun, Shah, Amishi Yogesh, Wang, Jianbo

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe17028-e17028, 1p

Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV).

Authors: Jiang, Cindy, Alhalabi, Omar, Haro-Silerio, Jaime, Qiao, Wei, Shah, Amishi Yogesh, Siefker-Radtke, Arlene O., Gao, Jianjun, Goswami, Sangeeta, Alva, Ajjai Shivaram, Koshkin, Vadim S., Guo, Charles, Campbell, Matthew T.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe16618-e16618, 1p

CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).

Authors: Johns, Andrew, Campbell, Matthew T, Msaouel, Pavlos, Jonasch, Eric, Hahn, Andrew Warren, Gao, Jianjun, Shah, Amishi Yogesh, Goswami, Sangeeta, Zurita, Amado J., Pagliaro, Lance C., Bilen, Mehmet Asim, Venkatesan, Aradhana M., Rao, Priya, Tamboli, Pheroze, Sircar, Kanishka, Slack Tidwell, Rebecca, Tannir, Nizar M.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4597-4597, 1p

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

Authors: Wang, Jianbo, Campbell, Matthew T, Shah, Amishi Yogesh, Goswami, Sangeeta, Msaouel, Pavlos, Alhalabi, Omar, Hahn, Andrew Warren, Kovitz, Craig A., Jana, Bagi RP, Araujo, John C., Gao, Jianjun, Zurita, Amado J., Jonasch, Eric, Corn, Paul Gettys, Tannir, Nizar M.

Source: Journal of Clinical Oncology; 2/21/2023 Supplement, Vol. 41, pTPS745-TPS745, 1p